Introduction
============

Extracranial vertebral aneurysms are rare vascular lesions and result from a variety of causes, such as bacterial infection, rheumatoid arthritis, injuries, neurofibromatosis type 1, fibromuscular dysplasia, and osteomyelitis. The location of the aneurysm has been reported as the first segment in 17.5%, the second in 70%, and the third in 12.5%.^[@B1]^ Remain untreated, they could encompass adverse outcomes including hemorrhage, enlargement, vessel occlusion, and distal embolism.^[@B2]^ The traditional treatment option was surgical correction for accessible lesions, and anticoagulation or antiplatelet therapy for inaccessible lesions.^[@B3]--[@B5]^ These options were frequently invasive or unsatisfactory, respectively. Endovascular treatment with stent placement and coil occlusion has become a common first-line treatment of pseudoaneurysm with the goal of parent artery preservation.^[@B6]--[@B8]^ Several case reports recently described endovascular procedures of treatment using a stent-graft for pseudoaneurysm or arteriovenous fistula of extracranial carotid or vertebral artery.^[@B9],[@B10]^ It would be still controversial to place a stent-graft in the treatment of an infection-related aneurysm. In this article we present our experience using a coronary stent-graft to treat a presumed pseudoaneurysm of the extracranial vertebral artery, which arose following local infection.

Case Report
===========

A 75-year-old man was hospitalized due to high fever and severe epigastric pain and was found to suffer from acute cholangitis, which progressed to sepsis and systemic multiple abscesses. One of the abscesses which compressed the trachea was surgically drained and tracheostomy was performed by otolaryngologists. The responsible bacteria of sepsis and the cervical abscess was methicillin-sensitive *Staphylococcus aureus*. Approximately 1 month after the drainage, a vertebral aneurysm was detected ventral to the spinal column at the C3/4 intervertebral level ([Fig. 1](#F1){ref-type="fig"}). The aneurysm continued growing enough to compress the trachea, though sepsis attained remission due to intensive antibiotic therapy ([Fig. 2](#F2){ref-type="fig"}). The aneurysm enlarged from 20 mm to 28 mm in height in a week.

Balloon test occlusion and aneurysm evaluation were performed. The diameters of the vertebral arteries are nearly equal. No neurological symptoms were observed while the right vertebral artery was occluded with a balloon catheter for 15 minutes. The neck width along the vertebral artery was 6.1 mm from the three-dimensional digital subtraction angiography. Endovascular treatment was indicated to prevent future bleeding and compressive airway obstruction. Aneurysm exclusion with a stent-graft was the procedure of choice to preserve the parent artery. Informed written consent for using stent-graft in the treatment of an extracranial vertebral aneurysm was obtained from the patient and his family, and an off-label use of the coronary stent-graft was approved by the Institutional Review Board of the Osaka Red Cross Hospital. Following a dual antiplatelet treatment with clopidogrel 75 mg and aspirin 100 mg per day for a week, the patient underwent endovascular treatment under local anesthesia. Heparin (5,000 IU) was intravenously administered immediately after a 6 Fr 25 cm introducer sheath (Terumo Corporation, Tokyo) was placed through the femoral artery, and appropriate dose of heparin was added as needed to maintain an activated clotting time (ACT) between 300 s and 330 s during the procedure. A 6F Launcher guiding catheter (Medtronic, Tokyo) was navigated to the right vertebral artery proximal to the aneurysm through the introducer sheath. Intravascular ultrasonography showed that the diameter of the proximal vertebral artery was media-media 4.2 × 4.2 mm and that of the distal vertebral artery was media-media 4.1 × 4.2 mm. Guardwire® (Medtronic, Tokyo) was advanced up to the right vertebral artery distal to the aneurysm. The balloon of Guardwire was inflated in the right vertebral artery just below the level of cervical atlas. We adopted this protection to prevent embolism which could be caused by endoleak. Jostent GraftMaster Coronary Stent Graft (Abbott Japan Co. Ltd., Tokyo) 4 × 19 mm was advanced over Guardwire, deployed across the aneurysm neck, and then dilated with 4 × 20 mm Submarine balloon (St. Jude Medical, Tokyo) to be fixed in the vessel. Inflation of the balloon to its nominal pressure 8 atmospheres failed to make the stent fit to the vessel wall and endoleak was followed. Additional inflation up to 14 atmospheres (4.33 mm in diameter) was necessary. Its rated burst pressure is 17 atmospheres. The balloon of Guardwire was deflated after blood was evacuated in the obstructed lumen in the right vertebral artery. Postoperative angiography showed that Jostent GraftMaster was deployed successfully with aneurysm exclusion and patency of the parent artery ([Fig. 3](#F3){ref-type="fig"}). The patient remained asymptomatic without neurological deficits or local pain. No distal embolism was detected with magnetic resonance image (MRI) 3 days after the procedure.

A dual antiplatelet treatment with clopidogrel 75 mg and aspirin 100 mg per day was continued for 6 months and was shifted to a single antiplatelet treatment with clopidogrel 75 mg per day thereafter. Cefazolin, piperacillin, and tazobactam were intravenously administered for a month after the procedure. Oral sulfamethoxazole-trimethoprim was supposed to be administered ever since. Follow-up computed tomography (CT) angiography after 4 years demonstrated that aneurysm exclusion and full patency of the stent-graft without deformation is preserved. Infectious symptoms have not been observed since the stent was placed ([Fig. 4](#F4){ref-type="fig"}).

Discussion
==========

We report the case of a 75-year-old man with an extracranial vertebral aneurysm which appeared associated with local or systemic infection treated with a stent-graft. Possible treatment options for this aneurysm would be surgical ligation of the parent artery, internal trapping of the vertebral artery, endovascular occlusion of the aneurysm, placement of a bare stent/stent-graft or combination of these procedures, etc.

The treatment of aneurysms in the cervical region as well as in other regions is also going through a transition, i.e., surgical treatment is replaced by endovascular treatment in many cases and stent-graft placement is gradually being prevailed. In 1991, the first aortic aneurysm treatment using a stent-graft was reported.^[@B11]^ This rapidly evolving technique is being widely adapted to the treatment of aneurysms and direct injuries of large vessels such as the aorta and the iliofemoral arteries etc.^[@B12],[@B13]^ In 2000, Simionato et al. reported the effectiveness of stent-graft therapy for a common carotid artery pseudoaneurysm.^[@B14]^ They described in their report that a stent-graft with a delivery system of sufficient length to reach the upper cervical region from a femoral artery access was not commercially available. Therefore, they needed to crimp a stent-graft manually on an angioplasty balloon catheter and advanced a guiding sheath as large as 9 Fr into a parent artery to deliver them. This has made it difficult to apply a stent-graft to the treatment of vertebral lesion as a first line option.

Stent-grafts available in our country are mainly designed for the application to the bile ducts or the peripheral vessels, of which delivery systems would be large in diameter and short in length for application to the vertebral artery. A stent-graft designed for the coronary artery appears suitable for the vertebral artery in diameter and also in length. In this report, we used Jostent GraftMaster Coronary Stent Graft to exclude the aneurysm and to preserve patency of the parent artery. It consists of two stainless steel flexible stents with an expandable polytetrafluoroethylene (PTFE) graft material wrapped between the two stents. The stent-graft varies 3.0--5.0 mm in diameter and 9--26 mm in length. Usable length of delivery system is 140--145 cm (a stent-graft 3.0--4.0 mm in diameter) or 150--155 cm (4.5--5.0 mm). The Food and Drug Administration (FDA) has approved GraftMaster for commercial use in selected patients under a Humanitarian Device Exemption (HDE) for use in the treatment of free perforations in native vessels or saphenous vein bypass grafts greater than or equal to 2.75 mm in diameter. These product features have advantage in application for the treatment of cervical or intracranial vessel lesions though GraftMaster is indeed designed only for coronary use. Several cases of the endovascular treatment in which GraftMaster was used for pseudoaneurysms of cervical or intracranial arteries have been reported.^[@B8],[@B15]^

The vessel lesion in this case was presumed to be pseudoaneurysm which arose due to systemic or local infection. Facing the treatment, we first thought that preservation of the affected vertebral artery was preferred though balloon test occlusion resulted in tolerable, because we were afraid that another pseudoaneurysm might actually arise on the ipsilateral carotid artery or the contralateral vertebral artery after our treatment even though infection had completely subsided. At this stage, we ruled out surgical ligation or internal trapping of the parent artery from the choices. Second, we anticipated that it might be less fraught with infection risk to place a stent-graft in the vessel lumen than to deploy a number of coils in the large aneurysm which extended into the space where an abscess usually exists. We were also afraid that large coil mass might compress trachea and later damage its wall. It would be still controversial to place a stent-graft as a foreign substance at an infection site. Some reports describe the cases with good results of the treatment with PTFE graft for mycotic aneurysm, others with bad results.^[@B16]--[@B18]^ It would be proper at least to avoid to place a stent-graft in the vicinity of infection site in the active stage. Since sepsis and the cervical abscess were completely abated in the present case, we finally chose stent-graft placement among treatment options understanding its potential risk of infection. In general, it is often difficult for a stent-graft to pass through a tortuous part of the artery and is usually unsuited to be deployed to a curved site. In our clinical experience, stubborn endoleak in the treatment with a stent-graft tends to occur more frequently at a lesion of the carotid artery than at that of the vertebral artery. This seems because the vertebral artery is supported by the transverse foramina of the vertebrae. The present case fortunately had favorable conditions for the treatment with a stent-graft except infection risk.

It also remains unclear how long the patient should be given antibiotics after stent-graft placement for an infection-related aneurysm. The present case had suffered from chronic rheumatoid arthritis for more than 20 years and was necessary to continue steroid and immunosuppressant. Therefore, oral sulfamethoxazole-trimethoprim was supposed to be administered for the rest of his life.

Regarding distal protection device, it is not obvious if the process is necessary. Though thrombi in an aneurysm are not likely to go through the stent mesh to the vessel lumen, it is not absolutely safe due to endoleak which may carry potential thrombi out of the aneurysm and cause embolism.

Conclusion
==========

The aneurysm of the extracranial vertebral artery was effectively excluded with a stent-graft. Jostent GraftMaster Coronary Stent Graft appears suitable device for the treatment of an aneurysm in the cervical region. It would be, however, still controversial to place a stent-graft in the treatment of an infection-related aneurysm.

![Contrast-enhanced computed tomography (CT) and CT angiography show a large aneurysm (*asterisk*) of the right extracranial vertebral artery. A: Axial view of enhanced CT. B: Frontal view of CT angiography.](nmc-55-852-g1){#F1}

![Digital subtraction angiography of the right vertebral artery shows an aneurysm located between transverse foramina of third and fourth cervical vertebrae. A, B: First examination; anteroposterior view and lateral, retrospectively. C, D: Second examination 7 days after the first. Anteroposterior view and lateral, retrospectively. The aneurysm grew from 20 mm to 28 mm in height.](nmc-55-852-g2){#F2}

![At the end of the treatment, the digital subtraction angiogram shows total exclusion of the aneurysm with preservation of a normal vertebral lumen. A: Anteroposterior view, B: lateral view. Arrows indicate both ends of the stent-graft.](nmc-55-852-g3){#F3}

![Computed tomography (CT) angiography with multi planer reconstruction 4 years after the procedure shows the stent-graft fully patent without deformation. Complete exclusion of the aneurysm was observed during the follow-up period. A: Anteroposterior view, B: oblique view.](nmc-55-852-g4){#F4}
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